Results 121 to 130 of about 28,422 (269)

Long-Term Omalizumab use in the Treatment of Exercise-Induced Anaphylaxis

Allergy & Rhinology, 2017
Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed.
Mark R. Peterson D.O., Christopher A. Coop M.D.   +1 more
doaj   +1 more source

Induced sputum versus exhaled nitric oxide for the evaluation of airway inflammation in allergic paediatric asthma patients treated with omalizumab [PDF]

, 2013
Our purpose is to determine the inflammatory changes in the airways of allergic paediatric asthma patients treated with omalizumab, measured by the percentage ofEl nostre objectiu és determinar els canvis inflamatoris en la via aèria de pacients ...
Domingo Miró, Xavier, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +2 more
core   +1 more source

Outcomes of off-label drug uses in hospitals: a multicentric prospective study [PDF]

, 2015
Purpose: The study aims to assess the clinical evidence, outcome and cost of off-label use of medicines in the hospital setting. Methods: A multicentric prospective cohort study of patients treated with off-label medicines was carried out in five ...
Agustí, Antonia, Alerany, C., Bonafont, X., Bosch Gil, Josep Àngel, Cano Marron, S. M., Danés, Immaculada, Ferrer, Assumpta, Gratacós, L., Martínez, J., Olmo, M., Pérez, A., Valderrama, A., Vallano Ferraz, Antonio   +12 more
core   +1 more source

How to evaluate a patient's response to anti-IgE

European Respiratory Review, 2007
Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled ...
S. T. Holgate
doaj  

Algorithms in Allergy: Hereditary Angioedema

Allergy, EarlyView.
Konrad Bork, Markus Magerl, Emel Aygören‐Pürsün, Henriette Farkas   +3 more
wiley   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

Scientific Reports
Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and urticaria. Although the efficacy of omalizumab has been well established, its safety profile is primarily derived from clinical trials with limited sample ...
Yongfu Song, Zhuang Wang, Na Wang, Xiaofei Xie, Tieshi Zhu, Yongji Wang   +5 more
doaj   +1 more source

Immunoglobulin E-Mediated Autoimmunity [PDF]

, 2018
The study of autoimmunity mediated by immunoglobulin E (IgE) autoantibodies, which may be termed autoallergy, is in its infancy. It is now recognized that systemic lupus erythematosus, bullous pemphigoid (BP), and chronic urticaria, both spontaneous and ...
Altrichter, Sabine, Church, Martin K., Maurer, Marcus, Metz, Martin, Scheffel, Jörg, Schmetzer, Oliver   +5 more
core   +1 more source

CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single‐Center Study

International Journal of Dermatology, EarlyView.
Personalized CSU care guided by CH50. ABSTRACT Background Chronic spontaneous urticaria (CSU) is frequently refractory to guideline‐based therapy, highlighting the need for predictive biomarkers. Dysregulation of the complement system has been implicated in CSU severity, but global complement activity has not been systematically evaluated.
Nidia Planella‐Fontanillas, Emilio Berna‐Rico, David Pesqué, Evelyn Andrades, Silvia Sánchez, Paloma Torres‐Bosó, Ramon Gimeno, Fernando Gallardo, Ramon M. Pujol, Ana M. Giménez‐Arnau   +9 more
wiley   +1 more source

Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium

ERJ Open Research, 2019
Background Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and its effectiveness.
Katia M.C. Verhamme, Catherine Lucet, Alain Van Meerhaeghe, Guy G.O. Brusselle, Marie-Laurence Lambert   +4 more
doaj   +1 more source